-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Kite Pharma, an editor of WuXi AppTec's content team, recently announced that the US FDA has accelerated the approval of the CAR-T therapy Yescarta (axicabtagene ciloleucel) as an extended indication for the treatment of relapsed/refractory follicular lymphoma (FL) Adult patients.
They have received at least two systemic treatments.
The press release stated that this is the first CAR-T cell therapy approved for the treatment of patients with indolent follicular lymphoma.
Follicular lymphoma is the most common form of indolent lymphoma and the second most common type of lymphoma in the world.
It accounts for approximately 22% of all lymphomas diagnosed worldwide.
Currently, after two or more lines of treatment, treatment options for relapsed/refractory follicular lymphoma are limited.
Yescarta is the second CAR-T cell therapy approved by the FDA for the treatment of adult patients with relapsed/refractory large B-cell lymphoma.
It guides and activates T cells to kill cancerous B cells by targeting the CD19 antigen on the surface of B cells.
This approval is based on the results of a single-arm, open-label study called ZUMA-5.
The results of the trial showed that 91% of patients with relapsed/refractory follicular lymphoma (n=81) responded to Yescarta, and 74% of them were in continuous remission after receiving treatment for 18 months.
At a median follow-up time of 14.
5 months, the median remission time has not yet been reached.
"Once the disease of a follicular lymphoma patient recurs, the duration of response to each round of treatment will become shorter and shorter.
"Dana-Farber Cancer Institute Immune Effector Cell Therapy Program Director Dr.
Caron A.
Jacobson said, "The five-year survival rate for patients receiving third-line treatment is only 20%.
Yescarta brings hope to these patients and adds an important option to the oncologist’s therapy arsenal.
"Note: This article is intended to introduce medical and health research, not a treatment plan recommendation.
If you need treatment plan guidance, please go to a regular hospital.
Reference: [1] US FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy.
Retrieved March 6, 2021, from https://
They have received at least two systemic treatments.
The press release stated that this is the first CAR-T cell therapy approved for the treatment of patients with indolent follicular lymphoma.
Follicular lymphoma is the most common form of indolent lymphoma and the second most common type of lymphoma in the world.
It accounts for approximately 22% of all lymphomas diagnosed worldwide.
Currently, after two or more lines of treatment, treatment options for relapsed/refractory follicular lymphoma are limited.
Yescarta is the second CAR-T cell therapy approved by the FDA for the treatment of adult patients with relapsed/refractory large B-cell lymphoma.
It guides and activates T cells to kill cancerous B cells by targeting the CD19 antigen on the surface of B cells.
This approval is based on the results of a single-arm, open-label study called ZUMA-5.
The results of the trial showed that 91% of patients with relapsed/refractory follicular lymphoma (n=81) responded to Yescarta, and 74% of them were in continuous remission after receiving treatment for 18 months.
At a median follow-up time of 14.
5 months, the median remission time has not yet been reached.
"Once the disease of a follicular lymphoma patient recurs, the duration of response to each round of treatment will become shorter and shorter.
"Dana-Farber Cancer Institute Immune Effector Cell Therapy Program Director Dr.
Caron A.
Jacobson said, "The five-year survival rate for patients receiving third-line treatment is only 20%.
Yescarta brings hope to these patients and adds an important option to the oncologist’s therapy arsenal.
"Note: This article is intended to introduce medical and health research, not a treatment plan recommendation.
If you need treatment plan guidance, please go to a regular hospital.
Reference: [1] US FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy.
Retrieved March 6, 2021, from https://
